Search

John M Maraganore

from Boston, MA
Age ~62
Get Report
Also known as:
John Dr Maraganore, John Michael Silvano Maraganore, Jean M Maraganore, John E
Phone and address:
1 Franklin St PH 2B, Boston, MA 02110
(617) 242-8225
Connected to:
Sami S Maragan, 38Adrian A Maragh, 59Demesha C Maragh, 34Tracy Maragh, 36Jill L Maraghy, 77Michael E Maraghy, 45Mitzie A Maraghy, 65Sarah J Maraglio, 37Alfred S Maragni, 67Joanne R Maragni, 56

John Maraganore Phones & Addresses

  • 1 Franklin St PH 2B, Boston, MA 02110 (617) 242-8225
  • 197 Pier 7, Charlestown, MA 02129 (617) 242-7270
  • 49 Pier 7, Charlestown, MA 02129 (617) 242-8225
  • 50 Pier 7, Charlestown, MA 02129
  • 84 Patrick Rd, Tewksbury, MA 01876
  • Paris, IL
  • Nantucket, MA
  • Dallas, TX
  • Chicago, IL
  • Salem, VA

Resumes

Resumes

John Maraganore Photo 1

Chief Executive Officer And Director

View page
Location:
33 Lafayette St, Waltham, MA 02453
Industry:
Biotechnology
Work:
Biotechnology Industry Organization Jun 2017 - May 2019
Chair
Takeda Oncology 2000 - 2002
Senior Vice President, Strategic Product Development
Takeda Oncology 1997 - 2002
Management Team and Corporate Officer
Alnylam Pharmaceuticals 1997 - 2002
Chief Executive Officer and Director
Takeda Oncology 1999 - 2000
Vice President, Mergers, Acquisitions and Strategic Planning
Education:
University of Chicago 1986
Doctorates, Doctor of Philosophy, Molecular Biology, Biochemistry University of Chicago 1985
Master of Science, Masters, Molecular Biology, Biochemistry University of Chicago 1984
Bachelors, Bachelor of Arts
John Maraganore Photo 2

Chief Executive Officer

View page
Location:
Boston, MA
Industry:
Biotechnology
Work:
Alnylam Pharmaceuticals
Chief Executive Officer

Business Records

Name / Title
Company / Classification
Phones & Addresses
John Maraganore
Director
Agios Pharmaceuticals
Pharmaceuticals · Biotechnical Research & Development · Commercial Physical Research
38 Sidney St, Cambridge, MA 02139
38 Sidney St 2 Floor, Cambridge, MA 02139
(617) 649-8600
John Maraganore
Director
TEMPERO PHARMACEUTICALS, INC
Commercial Physical Research
200 Technology Sq, Cambridge, MA 02139
Cambridge, MA 02139
(617) 374-8830
John Maraganore
Principal
Are Seven Nine Zero Memorial D
Clothing: Womens, Childrens, and Infants · Nonclassifiable Establishments · Whol Women's/Child's Clothing
790 Memorial Dr, Cambridge, MA 02139
John Maraganore
President
LEUKOSITE, INC
215 1 St, Cambridge, MA 02142
75 Sidney St, Cambridge, MA
John Maraganore
Treasurer
MILLENNIUM BIOTHERAPEUTICS, INC
640 Memorial Dr, Cambridge, MA 02139
75 Sidney St, Cambridge, MA
John M. Maraganore
Director
Archemix Corp
Commercial Physical Research Noncommercial Research Organization
148 Sidney St, Cambridge, MA 02139

Publications

Us Patents

Compositions And Methods For Inhibiting Expression Of Factor V Leiden Mutant Gene

View page
US Patent:
20100069461, Mar 18, 2010
Filed:
Nov 7, 2006
Appl. No.:
12/093235
Inventors:
Hans-Peter Vornlocher - Bayreuth, DE
John M. Maraganore - Charlestown MA, US
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
A61K 31/7105
C07H 21/02
C12N 5/10
C12N 15/74
A61P 9/00
US Classification:
514 44 A, 536 245, 435325, 4353201
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.

Compositions And Methods For Inhibiting Expression Of Factor V Leiden Mutant Gene

View page
US Patent:
20110130443, Jun 2, 2011
Filed:
Jan 20, 2011
Appl. No.:
13/010300
Inventors:
Hans-Peter Vornlocher - Bayreuth, DE
John M. Maraganore - Charlestown MA, US
International Classification:
A61K 31/713
C07H 21/04
C12N 5/10
C12N 15/63
A61P 7/02
US Classification:
514 44 A, 536 245, 435325, 4353201
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.

Cell-Based Methods And Reagents

View page
US Patent:
20130164329, Jun 27, 2013
Filed:
Feb 16, 2011
Appl. No.:
13/578886
Inventors:
Anthony Rossomando - Cambridge MA, US
John M. Maraganore - Cambridge MA, US
Stuart Pollard - Cambridge MA, US
Muthiah Manoharan - Cambridge MA, US
Assignee:
Alnylam Pharmaceuticals, Inc. - Cambridge MA
International Classification:
C12N 7/02
C12N 7/00
G01N 33/569
C12N 1/20
C12N 1/10
C12Q 1/70
A61K 39/15
US Classification:
4242151, 435 5, 435239, 4352351, 4352521, 4352581, 4352531, 4352582, 4352583
Abstract:
The present invention relates to compositions and methods for isolating cells devoid of unwanted viral contaminants, and to methods for preparing a virus stock substantially devoid of viral contaminants. Virus stocks, cells, and immunogenic reagents produced using such methods are also provided.

Novel Cytotoxic Protein

View page
US Patent:
49855417, Jan 15, 1991
Filed:
Apr 10, 1987
Appl. No.:
7/036840
Inventors:
John M. Maraganore - Waltham MA
Wayne R. Kindsvogel - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
C07K 1510
C07K 302
C07K 320
C07K 322
US Classification:
530370
Abstract:
Purified cytotoxic proteins for use within therapeutic compositions are disclosed. The proteins inhibit protein synthesis in vitro, exhibit abortifacient activity in mice, and contain proline residues with equivalent positions at residue 43 and residue 46 in ricin A-chain. A method for preparing such a cytotoxic protein from the tissue of Trichosanthes kirilowii is also disclosed. The proteins may also be used within a method for inhibiting protein synthesis in selected cells.

Cytotoxic Protein From Trichosanthes Kirilowii

View page
US Patent:
51495287, Sep 22, 1992
Filed:
Nov 13, 1989
Appl. No.:
7/434173
Inventors:
John M. Maraganore - Waltham MA
Wayne R. Kindsvogel - Seattle WA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 3944
C07K 1510
C07K 1702
US Classification:
424 8591
Abstract:
Purified cytotoxic proteins for use within therapeutic compositions are disclosed. The proteins inhibit protein synthesis in vitro, exhibit abortifacient activity in mice, and contain proline residues with equivalent positions at residue 43 and residue 46 in ricin A-chain. A method for preparing such a cytotoxic protein from the tissue of Trichosanthes kirilowii is also disclosed. The proteins may also be used within a method for inhibiting protein synthesis in selected cells.

Methods For Coating Invasive Devices With Inhibitors Of Thrombin

View page
US Patent:
56913117, Nov 25, 1997
Filed:
May 11, 1995
Appl. No.:
8/439297
Inventors:
John M. Maraganore - Concord MA
John W. Fenton - Malden Bridge NY
Toni Kline - Cambridge MA
Assignee:
Biogen, Inc. - Cambridge MA
International Classification:
A61K 3800
US Classification:
514 12
Abstract:
This invention relates to novel biologically active molecules which bind to and inhibit thrombin. Specifically, these molecules are characterized by a thrombin anion-binding exosite association moiety (ABEAM); a linker portion of at least 18. ANG. in length; and a thrombin catalytic site-directed moiety (CSDM). This invention also relates to compositions, combinations and methods which employ these molecules for therapeutic, prophylactic and diagnostic purposes.

Methods And Compositions For Inhibiting Platelet Aggregation

View page
US Patent:
52565599, Oct 26, 1993
Filed:
Mar 27, 1991
Appl. No.:
7/677609
Inventors:
John M. Maraganore - Tewksbury MA
Joseph A. Jakubowski - Indianapolis IN
Assignee:
Biogen, Inc. - Cambridge MA
Trustees of Boston University - Boston MA
International Classification:
C12N 506
A61K 3702
A61K 39395
C07K 706
US Classification:
4352402
Abstract:
This invention relates to anticoagulant and platelet inhibitory compositions, combinations and methods characterized by biologically active peptides which display the anticoagulant and platelet inhibitory activities of hirudin, or analogs thereof, for therapeutic and prophylactic purposes. The methods, compositions and combinations of this invention are advantageously useful for decreasing or preventing platelet aggregation and platelet activation in a patient or a biological sample. These methods, compositions and combinations are particularly useful in patients for whom standard heparin therapy is contraindicated due to a history of heparin-induced thrombocytopenia or an antithrombin III deficiency. This invention also relates to methods, compositions and combinations for treating extracorporeal blood and for increasing platelet storage life.

A Method Of Inhibiting Fertilization By Alpha-1-Antitrypsin Or Antithrombin Iii

View page
US Patent:
55456154, Aug 13, 1996
Filed:
Sep 22, 1994
Appl. No.:
8/312010
Inventors:
John M. Maraganore - Waltham MA
Assignee:
ZymoGenetics, Inc. - Seattle WA
International Classification:
A61K 3702
US Classification:
514 2
Abstract:
Methods for inhibiting fertilization in warm-blooded animals are disclosed. The methods generally comprise administering to the animal an effective amount of a composition comprising a protein that forms a covalent complex with acrosin, and a physiologically acceptable carrier or diluent. Suitable proteins for use in the methods include members of the serpin family of proteins, such as alpha-1-antitrypsin.
Control profile
John M Maraganore from Boston, MA, age ~62 Get Report